ACP3 and Familial prostate cancer: This immunotherapy involves ex vivo stimulation of autologous, blood-derived antigen presenting cells from prostate cancer patients that are pulsed with a prostate cancer-associated antigen [PAP (prostate acid phosphatase)–GM-CSF fusion protein].